体外膜肺氧合生命支持期间抗真菌药物的药代动力学特征  

Pharmacokinetic profiles of antifungal drugs during extracorporeal membrane oxygenation life support

作　　者：樊登云 李珊 柳熠鑫 任菲菲 杨珍珍 武玺坤 马颖超[1] 张志清[1] 张亚坤[1] Fan Dengyun;Li Shan;Liu Yixin;Ren Feifei;Yang Zhenzhen;Wu Xikun;Ma Yingchao;Zhang Zhiqing;Zhang Yakun(Department of Pharmacy,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei,China)

机构地区：[1]河北医科大学第二医院药学部,石家庄050000

出　　处：《中华危重病急救医学》2022年第1期100-104,共5页Chinese Critical Care Medicine

基　　金：河北省自然科学基金(H2021206384)。

摘　　要：体外膜肺氧合(ECMO)作为一种可以替代肺脏和心脏功能的生命支持技术,在各种危重症呼吸、循环衰竭中的应用逐渐增多。由于自身严重疾病及介入性导管的使用,接受ECMO生命支持的患者常使用广谱抗微生物药物,进而增加了真菌感染的风险。ECMO期间发生真菌感染可导致病死率增加,如何有效控制真菌感染是临床医生面临的棘手问题。采用抗真菌药物治疗期间,患者病理生理状况及ECMO的氧合膜、循环管路等因素均有可能改变抗真菌药物的药代动力学特征,进而影响药物临床疗效。本文对ECMO支持期间抗真菌药物的药代动力学特征进行分析综述,以期为临床抗真菌治疗提供参考。Extracorporeal membrane oxygenation(ECMO),a kind of life support technology that can replace lung and heart function,is widely used in critical respiratory and circulatory exhaustion.Because of the serious diseases and the use of interventional catheters,patients receiving ECMO life support are often administrated with broad-spectrum antimicrobial agents,which increase the risk of fungal infection.Fungal infection during ECMO can increase mortality.How to effectively control fungal infection is a thorny problem faced by clinicians.During the treatment of ECMO,the patient's physiological status,ECMO oxygenation membrane,circulation pipeline and other factors may change the pharmacokinetic profiles of antifungal drugs,thereby affect the clinical efficacy of drugs.This artical reviews the pharmacokinetic characteristics of antifungal drugs during ECMO support,in order to provide references for clinical antifungal treatment.

关 键 词：抗真菌药物 药代动力学 体外膜肺氧合 治疗药物监测 

分 类 号：R969.1[医药卫生—药理学]